I welcome the recent articles on the need for rehabilitation after critical illness and the lack of appropriate resources to provide what is needed.12 The deficiencies […]
The US Food and Drug Administration (FDA) has approved aducanumab (Aduhelm)—a drug which aims to delay clinical decline in patients with Alzheimer’s disease—despite concerns over a […]
AbstractDelirium, a form of acute brain dysfunction, is very common in the critically ill adult patient population. Although its pathophysiology is poorly understood, multiple factors associated […]